Overview
Relief Therapeutics Holding AG is a Swiss-based biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients suffering from severe diseases with high unmet medical need. The company's primary focus is on the development of drugs for respiratory diseases, particularly COVID-19. Its flagship project is RLF-100 (Aviptadil), a synthetic form of a naturally occurring peptide that protects the lung, which is currently in advanced clinical trials as a treatment for critical COVID-19 patients.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is 4.05 MM.
- The operating income for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -8.16 MM.
- The net income for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -17.04 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 4.05 | -8.16 | -17.04 |
| 2025-03-31 | 6.24 | -7.89 | -17.08 |
| 2024-12-31 | 8.42 | -7.62 | -17.12 |
| 2024-06-30 | 8.59 | -12.23 | -46.24 |
| 2024-03-31 | 7.31 | -16.04 | -72.21 |
| 2023-12-31 | 6.03 | -19.85 | -98.18 |
| 2023-09-30 | 5.95 | -23.08 | -89.48 |
| 2023-06-30 | 5.86 | -26.56 | -80.79 |
| 2023-03-31 | 5.97 | -30.88 | -65.79 |
| 2022-12-31 | 6.08 | -34.96 | -50.79 |
| 2022-09-30 | 6.32 | -37.04 | -48.66 |
| 2022-06-30 | 6.56 | -39.13 | -46.53 |
| 2022-03-31 | 4.94 | -36.68 | -40.62 |
| 2021-12-31 | 3.32 | -34.24 | -34.70 |
| 2021-09-30 | 1.66 | -32.72 | -32.73 |
| 2021-06-30 | -31.21 | -30.76 | |
| 2021-03-31 | -25.29 | -19.29 | |
| 2020-12-31 | -19.36 | -7.83 | |
| 2020-09-30 | -11.70 | -3.24 |
Income Statement: EPS
- The earnings per share basic for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -1.36.
- The earnings per share diluted for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -1.36.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | -1.36 | -1.36 |
| 2025-03-31 | -1.36 | -1.36 |
| 2024-12-31 | -1.37 | |
| 2024-06-30 | -3.70 | -3.70 |
| 2024-03-31 | -5.96 | -5.96 |
| 2023-12-31 | -8.35 | |
| 2023-09-30 | -7.89 | -7.89 |
| 2023-06-30 | -7.40 | -7.40 |
| 2023-03-31 | -6.12 | -6.12 |
| 2022-12-31 | -4.80 | |
| 2022-09-30 | -4.73 | -4.73 |
| 2022-06-30 | -4.65 | -4.65 |
| 2022-03-31 | -4.28 | -4.28 |
| 2021-12-31 | -3.86 | |
| 2021-09-30 | -3.97 | -3.97 |
| 2021-06-30 | -4.09 | -4.09 |
| 2021-03-31 | -2.85 | -2.85 |
| 2020-12-31 | -1.30 | |
| 2020-09-30 | -0.57 | -0.57 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -3.51 MM.
- The cash from investing activities for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is 5.70 MM.
- The cash from financing activities for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.30 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | -3.51 | 5.70 | -0.30 |
| 2025-03-31 | -3.21 | 5.05 | -0.58 |
| 2024-12-31 | -2.92 | 4.40 | -0.86 |
| 2024-06-30 | -10.31 | 8.91 | -0.74 |
| 2024-03-31 | -13.96 | 8.80 | 1.66 |
| 2023-12-31 | -17.61 | 8.70 | 4.05 |
| 2023-09-30 | -18.74 | 2.62 | 4.99 |
| 2023-06-30 | -19.86 | -3.46 | 5.93 |
| 2023-03-31 | -21.99 | -5.73 | 6.17 |
| 2022-12-31 | -24.13 | -8.00 | 6.42 |
| 2022-09-30 | -28.42 | -5.72 | 24.99 |
| 2022-06-30 | -32.71 | -3.45 | 43.57 |
| 2022-03-31 | -34.21 | -16.86 | 55.63 |
| 2021-12-31 | -35.72 | -30.26 | 67.69 |
| 2021-09-30 | -34.25 | -30.79 | 76.32 |
| 2021-06-30 | -32.78 | -31.32 | 84.95 |
| 2021-03-31 | -25.52 | -14.16 | 71.57 |
| 2020-12-31 | -18.25 | 3.00 | 58.20 |
| 2020-09-30 | -10.87 | 2.88 | 30.27 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | |||
| 2025-03-31 | |||
| 2024-12-31 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | ||
| 2025-03-31 | ||
| 2024-12-31 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2022-09-30 | ||
| 2022-06-30 | ||
| 2022-03-31 | ||
| 2021-12-31 | ||
| 2021-09-30 | ||
| 2021-06-30 | ||
| 2021-03-31 | ||
| 2020-12-31 | ||
| 2020-09-30 |
Management Effectiveness
- The roa for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.24.
- The roe for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.35.
- The roic for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.44.
- The croic for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is 0.01.
- The ocroic for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.08.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.24 | -0.35 | -0.44 | 0.01 | -0.08 |
| 2025-03-31 | 0.00 | 0.00 | |||
| 2024-12-31 | -0.61 | -0.89 | -0.89 | -0.04 | -0.20 |
| 2024-06-30 | -0.77 | ||||
| 2024-03-31 | -0.68 | ||||
| 2023-12-31 | -0.62 | -1.63 | -0.20 | ||
| 2023-09-30 | -0.36 | -0.50 | |||
| 2023-06-30 | -0.50 | ||||
| 2023-03-31 | -0.41 | ||||
| 2022-12-31 | -0.19 | -0.27 | -0.33 | -0.06 | -0.19 |
| 2022-09-30 | -0.27 | ||||
| 2022-06-30 | -0.37 | ||||
| 2022-03-31 | -0.33 | ||||
| 2021-12-31 | -0.52 | ||||
| 2021-09-30 | -0.49 | ||||
| 2021-06-30 | -1.27 | ||||
| 2021-03-31 | -0.80 | ||||
| 2020-12-31 | -0.55 | ||||
| 2020-09-30 | -0.23 |
Gross Margins
- The gross margin for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is 0.69.
- The net margin for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -2.03.
- The operating margin for Relief Therapeutics Holding SA - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.91.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | 0.69 | -2.03 | -0.91 |
| 2025-03-31 | |||
| 2024-12-31 | 0.69 | -5.38 | -1.43 |
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | 0.75 | -13.78 | -4.53 |
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | 0.79 | -7.70 | -5.88 |
| 2022-09-30 | |||
| 2022-06-30 | |||
| 2022-03-31 | |||
| 2021-12-31 | |||
| 2021-09-30 | |||
| 2021-06-30 | |||
| 2021-03-31 | |||
| 2020-12-31 | |||
| 2020-09-30 |
Identifiers and Descriptors
| Central Index Key (CIK) |
